BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32613555)

  • 1. The Master of Puppets: Pleiotropy of PDGFRB and its Relationship to Multiple Diseases.
    Moura DAP; de Oliveira JRM
    J Mol Neurosci; 2020 Dec; 70(12):2102-2106. PubMed ID: 32613555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of the phenotype of Kosaki overgrowth syndrome.
    Minatogawa M; Takenouchi T; Tsuyusaki Y; Iwasaki F; Uehara T; Kurosawa K; Kosaki K; Curry CJ
    Am J Med Genet A; 2017 Sep; 173(9):2422-2427. PubMed ID: 28639748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
    Bredrup C; Stokowy T; McGaughran J; Lee S; Sapkota D; Cristea I; Xu L; Tveit KS; Høvding G; Steen VM; Rødahl E; Bruland O; Houge G
    Eur J Hum Genet; 2019 Apr; 27(4):574-581. PubMed ID: 30573803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premature Aging Syndrome, Penttinen Type: Report of a Chinese Case with a PDGFRB Mutation.
    Zhang Z; Zheng S; Zheng S; Wang Y; Xu XG; Gao XH; Chen HD
    Acta Derm Venereol; 2018 Oct; 98(9):912-913. PubMed ID: 29944170
    [No Abstract]   [Full Text] [Related]  

  • 5. A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome.
    Johnston JJ; Sanchez-Contreras MY; Keppler-Noreuil KM; Sapp J; Crenshaw M; Finch NA; Cormier-Daire V; Rademakers R; Sybert VP; Biesecker LG
    Am J Hum Genet; 2015 Sep; 97(3):465-74. PubMed ID: 26279204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling.
    Nédélec A; Guérit EM; Dachy G; Lenglez S; Wong LS; Arts FA; Demoulin JB
    J Cell Mol Med; 2022 Jul; 26(14):3902-3912. PubMed ID: 35689379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDGFRB mutation causes autosomal-dominant Penttinen syndrome.
    Aminkeng F
    Clin Genet; 2015 Dec; 88(6):531. PubMed ID: 26507258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel de novo PDGFRB variant in a child with severe cerebral malformations, intracerebral calcifications, and infantile myofibromatosis.
    Guimier A; Gordon CT; Hully M; Blauwblomme T; Minard-Colin V; Bole-Feysot C; Nitschké P; Oufadem M; Boddaert N; Sarnacki S; Amiel J
    Am J Med Genet A; 2019 Jul; 179(7):1304-1309. PubMed ID: 31004414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First case report of Penttinen syndrome from India.
    Aggarwal B; Correa ARE; Gupta N; Jana M; Kabra M
    Am J Med Genet A; 2022 Feb; 188(2):683-687. PubMed ID: 34799960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
    Arts FA; Chand D; Pecquet C; Velghe AI; Constantinescu S; Hallberg B; Demoulin JB
    Oncogene; 2016 Jun; 35(25):3239-48. PubMed ID: 26455322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions.
    Bredrup C; Cristea I; Safieh LA; Di Maria E; Gjertsen BT; Tveit KS; Thu F; Bull N; Edward DP; Hennekam RCM; Høvding G; Haugen OH; Houge G; Rødahl E; Bruland O
    Hum Mol Genet; 2021 Mar; 30(1):72-77. PubMed ID: 33450762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.
    Arts FA; Sciot R; Brichard B; Renard M; de Rocca Serra A; Dachy G; Noël LA; Velghe AI; Galant C; Debiec-Rychter M; Van Damme A; Vikkula M; Helaers R; Limaye N; Poirel HA; Demoulin JB
    Hum Mol Genet; 2017 May; 26(10):1801-1810. PubMed ID: 28334876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infantile Myofibromatosis With Intracranial Extradural Involvement and PDGFRB Mutation: A Case Report and Review of the Literature.
    Al Qawahmed R; Sawyer SL; Vassilyadi M; Qin W; Boycott KM; Michaud J
    Pediatr Dev Pathol; 2019; 22(3):258-264. PubMed ID: 30103666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Segmental overgrowth and aneurysms due to mosaic PDGFRB p.(Tyr562Cys).
    Chenbhanich J; Hu Y; Hetts S; Cooke D; Dowd C; Devine P; ; Russell B; Kang SHL; Chang VY; Abla AA; Cornett P; Yeh I; Lee H; Martinez-Agosto JA; Frieden IJ; Shieh JT
    Am J Med Genet A; 2021 May; 185(5):1430-1436. PubMed ID: 33683022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous PDGFRB Mutation in a Three-generation Family with Autosomal Dominant Infantile Myofibromatosis.
    Lepelletier C; Al-Sarraj Y; Bodemer C; Shaath H; Fraitag S; Kambouris M; Hamel-Teillac D; El Shanti H; Hadj-Rabia S
    Acta Derm Venereol; 2017 Jul; 97(7):858-859. PubMed ID: 28417142
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sporadic infantile myofibromatosis: Mutations with PDGFRB gain-of-function].
    Dereure O
    Ann Dermatol Venereol; 2017; 144(8-9):574-575. PubMed ID: 28756885
    [No Abstract]   [Full Text] [Related]  

  • 17. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
    Wenger TL; Bly RA; Wu N; Albert CM; Park J; Shieh J; Chenbhanich J; Heike CL; Adam MP; Chang I; Sun A; Miller DE; Beck AE; Gupta D; Boos MD; Zackai EH; Everman D; Ganapathi S; Wilson M; Christodoulou J; Zarate YA; Curry C; Li D; Guimier A; Amiel J; Hakonarson H; Webster R; Bhoj EJ; Perkins JA; Dahl JP; Dobyns WB
    Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.
    Iznardo H; Bredrup C; Bernal S; Gladkauskas T; Mascaró JM; Roé E; Baselga E
    Am J Med Genet A; 2022 Apr; 188(4):1233-1238. PubMed ID: 34894066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recurrent PDGFRB mutation causes familial infantile myofibromatosis.
    Cheung YH; Gayden T; Campeau PM; LeDuc CA; Russo D; Nguyen VH; Guo J; Qi M; Guan Y; Albrecht S; Moroz B; Eldin KW; Lu JT; Schwartzentruber J; Malkin D; Berghuis AM; Emil S; Gibbs RA; Burk DL; Vanstone M; Lee BH; Orchard D; Boycott KM; Chung WK; Jabado N
    Am J Hum Genet; 2013 Jun; 92(6):996-1000. PubMed ID: 23731537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib.
    Weller JM; Keil VC; Gielen GH; Herrlinger U; Schäfer N
    Am J Med Genet A; 2019 Sep; 179(9):1895-1897. PubMed ID: 31291054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.